William Anderson, MD
Family Medicine · Rio Rancho, NMNPI 1194800334
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AstraZeneca at 43.8% of the total. Among family medicine clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $49.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Lilly USA, LLC$492
- AbbVie$294
- Idorsia Pharmaceuticals US Inc$243
- Amarin Pharma, Inc.$170
- plus $893 from 12 others
What the payments were for
- Food & beverage$5,55099%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $2,446 |
| Novo Nordisk | 31 | $1,044 |
| Lilly USA, LLC | 7 | $492 |
| AbbVie | 17 | $294 |
| Idorsia Pharmaceuticals US Inc | 2 | $243 |
| Amarin Pharma, Inc. | 5 | $170 |
| Boehringer Ingelheim | 2 | $136 |
| Genentech USA, Inc. | 1 | $126 |
| Bayer | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $104 |
| Abbott | 1 | $103 |
| Amgen | 1 | $94 |
| Merck | 3 | $62 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Gilead | 1 | $18 |
| Medline Industries LP | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,582 in reported general payments places this provider in the 95th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 130 | $104,613 |
| MounjaroTirzepatide | 74 | $89,648 |
| OzempicSemaglutide | 71 | $67,191 |
| XareltoRivaroxaban | 45 | $41,808 |
| EliquisApixaban | 42 | $40,280 |
| JardianceEmpagliflozin | 47 | $37,443 |
| TrulicityDulaglutide | 26 | $26,021 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $19,768 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $14,157 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $10,684 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 351 | $10,387 |
| Spiriva RespimatTiotropium Bromide | 18 | $9,372 |
| Varenicline Tartrate | 23 | $7,035 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 137 | $5,066 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $4,814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $492 | $115,669100 claims |
| AstraZenecaFarxiga, Symbicort | $2,446 | $115,297166 claims |
| Novo NordiskOzempic | $1,044 | $67,19171 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $136 | $46,81565 claims |
| MerckDulera | $62 | $4,13812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Rio Rancho
- Harold McFarlingFarmington$160K
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
- Wendy JohnsonSanta Fe$37K
- Delliah StamppLas Cruces$21K
- Conchita PazLas Cruces$16K
- Sergio HuertaLas Cruces$11K
- Timothy GrenemyerAlbuquerque$10K
- Cheri BlackstenAlbuquerque$9K
- Brenda CuellarLas Cruces$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.